Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Resonance Health | INDUSTRY |
This retrospective observational study will evaluate high-dose methotrexate patterns of use, supportive care measures used during high-dose methotrexate chemotherapy, along with the incidence of delayed elimination of methotrexate, acute kidney injury and any associated impact of delayed elimination of methotrexate on future courses of chemotherapy and disease outcomes in adults and children with cancer.
The study will compare current practice with existing guidelines and best practices to identify potential gaps in the management of high-dose methotrexate administration and delayed elimination of methotrexate. The study will identify variations in practice and outcomes in different study centers, countries, cancer types, patient age groups, by different methotrexate doses and infusion times and different supportive care measures used. The study will also document the proportion of high-dose methotrexate courses in which glucarpidase has been used and any toxicities attributable to the use of glucarpidase.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients Treated With High-dose Methotrexate | Patients with a diagnosis of any cancer receiving high-dose methotrexate chemotherapy. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| High-dose methotrexate | Drug | High-dose methotrexate |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Delayed Elimination of Methotrexate | Incidence of delayed elimination of methotrexate after high-dose methotrexate chemotherapy, defined by Ramsey criteria. | 0-48 hours from the start of high-dose methotrexate infusion. |
| Acute Kidney Injury | Incidence of acute kidney injury of any grade after high-dose methotrexate chemotherapy. | 0-48 hours from the start of high-dose methotrexate infusion. |
| Severe Delayed Elimination of Methotrexate | Incidence of severe delayed elimination of methotrexate after high-dose methotrexate chemotherapy, defined as a methotrexate level ≥2 standard deviations above the population mean at 36, 42, or 48 hours from the start of high-dose methotrexate infusion and with the presence of acute kidney injury of any grade. | 0-48 hours from the start of high-dose methotrexate infusion. |
| Measure | Description | Time Frame |
|---|---|---|
| Severity of Acute Kidney Injury | Severity of occurrences of acute kidney injury using CTCAE v5 criteria. | 0-48 hours from the start of high-dose methotrexate infusion. |
| Hospital Length of Stay |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The study will be conducted at approximately 10 European sites where high-dose methotrexate infusions are administered. Sites will be selected to ensure a balanced accrual of children and adults treated with high-dose methotrexate.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Lois Wallace | Contact | +1 945 239 1690 | Lois.wallace@btgsp.com | |
| Jennie Molland | Contact | +44 1239 851122 | Jennie.molland@btgsp.com |
| Name | Affiliation | Role |
|---|---|---|
| Carmelo Rizzari, MD | University of Milano-Bicocca, Pediatric Hematology Oncology Unit MBBM Foundation | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Assistance Publique Hôpitaux de Marseille (APHM), La Timone Hospital | Recruiting | Marseille | 13354 | France |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 29079637 | Background | Ramsey LB, Balis FM, O'Brien MM, Schmiegelow K, Pauley JL, Bleyer A, Widemann BC, Askenazi D, Bergeron S, Shirali A, Schwartz S, Vinks AA, Heldrup J. Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist. 2018 Jan;23(1):52-61. doi: 10.1634/theoncologist.2017-0243. Epub 2017 Oct 27. | |
| 32558929 |
| Label | URL |
|---|---|
| A pharmacokinetic model for the dose of methotrexate to display the concentration vs time curve for an individual patient overlaid upon the population-predicted curve for that dose. | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D058186 | Acute Kidney Injury |
| D064420 | Drug-Related Side Effects and Adverse Reactions |
| D019337 | Hematologic Neoplasms |
| D014869 | Water Intoxication |
| D012516 | Osteosarcoma |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D008727 | Methotrexate |
| C000629556 | glucarpidase |
| ID | Term |
|---|---|
| D000630 | Aminopterin |
| D011622 | Pterins |
| D011621 | Pteridines |
| D006574 | Heterocyclic Compounds, 2-Ring |
Not provided
Not provided
Not provided
Not provided
Not provided
| Glucarpidase |
| Drug |
Glucarpidase |
|
Duration of hospitalization.
| Assessed through study completion, up to 2 years after enrollment. |
| Hospital Readmission | Incidence of hospital readmission. | Within 14 days of high-dose methotrexate infusion. |
| Delay of Subsequent Chemotherapy | Occurrence of delays to further blocks of chemotherapy resulting from delayed methotrexate elimination. | Within 14 days of high-dose methotrexate infusion. |
| Dose Reduction or Omission of Subsequent High-dose Methotrexate Therapy | Occurrence of dose reduction or omission of high-dose methotrexate from further cycles of chemotherapy resulting from delayed methotrexate elimination. | Within 14 days of high-dose methotrexate infusion. |
| Event-Free Survival | "Events" include death, relapse, abandonment, or refusal of treatment. | 3, 5, and 10 years. |
| Overall Survival | All-cause mortality as well as mortality separately due to disease progression or toxicity. | 3, 5, and 10 years. |
| Glucarpidase-Related Toxicity | Occurrence of toxicities associated with glucarpidase, including frequency, severity (using CTCAE v5 criteria) and including documenting any toxicities of grade 3 or higher. | 15 minutes post-glucarpidase through discharge. |
| Methotrexate Clearance after Glucarpidase | MTX levels. | 15 minutes post-glucarpidase through discharge. |
| Serum Creatinine Level | Renal function, as measured by serum creatinine level. | 15 minutes post-glucarpidase through discharge. |
| Use of Subsequent High-Dose Methotrexate After Glucarpidase | Occurrence of subsequent high-dose methotrexate chemotherapy cycles given after glucarpidase. | Within 14 days of high-dose methotrexate infusion. |
| Disease Outcome After Glucarpidase | Disease outcome after glucarpidase | 3, 5, and 10 years. |
| Use of Hyperhydration | Incidence of the use of hyperhydration supportive care measures during high-dose methotrexate chemotherapy. | Assessed at time of hospital discharge. |
| Use of Leucovorin | Incidence of the use of leucovorin during high-dose methotrexate chemotherapy. | Assessed at time of hospital discharge. |
| Use of Dialysis or Hemofiltration | Incidence of the use of dialysis or hemofiltration during high-dose methotrexate chemotherapy. | Assessed at time of hospital discharge. |
| Use of Oral Methotrexate Binders | Incidence of the use of oral methotrexate binders (cholestyramine, activated charcoal) during high-dose methotrexate chemotherapy. | Assessed at time of hospital discharge. |
| Creatinine Clearance | Renal function, as measured by creatinine estimate | 15 minutes post-glucarpidase through discharge. |
| Need for Dialysis | Renal function, as measured by need for dialysis. | 15 minutes post-glucarpidase through discharge. |
| University of Milan-Bicocca | Recruiting | Monza | 20900 | Italy |
|
| Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR) | Recruiting | Barcelona | 08035 | Spain |
|
| Fundación Privada Instituto de Investigación Oncológica de Vall d'Hebron (VHIO) | Recruiting | Barcelona | 08035 | Spain |
|
| Hospital Universitario Reina Sofía | Recruiting | Córdoba | 14004 | Spain |
|
| Background |
| Taylor ZL, Mizuno T, Punt NC, Baskaran B, Navarro Sainz A, Shuman W, Felicelli N, Vinks AA, Heldrup J, Ramsey LB. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. Clin Pharmacol Ther. 2020 Sep;108(3):635-643. doi: 10.1002/cpt.1957. Epub 2020 Jul 18. |
| Voraxaze Summary of Product Characteristics (SmPC) | View source |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D064419 | Chemically-Induced Disorders |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D014883 | Water-Electrolyte Imbalance |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D011041 | Poisoning |
| D018213 | Neoplasms, Bone Tissue |
| D009372 | Neoplasms, Connective Tissue |
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
| D012509 | Sarcoma |
| D000072471 |
| Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |